Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.

This week, we break down:

Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis
The future of autoimmune disease treatment: genetically modified T cells
What policies people actually support (and will pay for) to reduce skin cancer rates
JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for
The latest on rising contact allergens: which ones are on the move and why

Packed with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.

Don’t miss out—hit play for your weekly dose of dermatology insights!

For links to all articles visit ScholarsinMedicine.com

1. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
2. Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid
3. Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
4. Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
5. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
6. Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries
7. North American Contact Dermatitis Group Patch Test Results: 2021–2022

The Cutting Edge of Dermatology: New Data, Hot Topics, and Clinical Pearls

Derms on Drugs

The Cutting Edge of Dermatology: New Data, Hot Topics, and Clinical Pearls